12 citations
,
August 2020 in “Annals of Oncology” This study found that androgen deprivation therapy in prostate cancer patients was associated with fewer SARS-CoV-2 infections but did not reduce COVID-19 disease severity or hospitalizations.
1 citations
,
March 2021 in “The Journal of Sexual Medicine” This study reported that testosterone replacement therapy was not linked to worse COVID-19 outcomes in men, though the data showed high hospitalization and fatality rates that suggest otherwise.
3 citations
,
March 2021 in “Journal of the European Academy of Dermatology and Venereology” This letter to the editor discusses the controversy surrounding the use of anti-androgen therapy for COVID-19 without providing new clinical evidence, and calls for caution in making extraordinary claims.
December 2022 in “Urology Herald” This review examines existing research on androgen deprivation therapy and its effects on male sex hormones in relation to COVID-19, but reports no new clinical findings.
5 citations
,
December 2022 in “Viruses” This review highlights recent insights into using antiandrogens as preventive and therapeutic measures against COVID-19, emphasizing their role in blocking viral infection by modulating androgen-mediated host protease TMPRSS2 and cell entry protein ACE2, with varying success in clinical trials.